PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-57.23%
Revenue decline while GNPX shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-57.23%
Gross profit decline while GNPX shows 54.37% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
-15.08%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-0.47%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.89%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-10.89%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
3.20%
D&A growth while GNPX reduces D&A. John Neff would investigate differences.
5.74%
EBITDA growth below 50% of GNPX's 38.56%. Michael Burry would check for structural issues.
-120.42%
EBITDA margin decline while GNPX shows 0.00% growth. Joel Greenblatt would examine position.
5.53%
Operating income growth below 50% of GNPX's 38.58%. Michael Burry would check for structural issues.
-120.91%
Operating margin decline while GNPX shows 0.00% growth. Joel Greenblatt would examine position.
3.85%
Other expenses growth while GNPX reduces costs. John Neff would investigate differences.
5.62%
Pre-tax income growth below 50% of GNPX's 38.58%. Michael Burry would check for structural issues.
-120.69%
Pre-tax margin decline while GNPX shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
5.62%
Net income growth below 50% of GNPX's 38.58%. Michael Burry would check for structural issues.
-120.69%
Net margin decline while GNPX shows 0.00% growth. Joel Greenblatt would examine position.
13.79%
EPS growth below 50% of GNPX's 40.88%. Michael Burry would check for structural issues.
13.79%
Diluted EPS growth below 50% of GNPX's 40.88%. Michael Burry would check for structural issues.
10.10%
Share count reduction below 50% of GNPX's 4.04%. Michael Burry would check for concerns.
10.10%
Diluted share reduction below 50% of GNPX's 4.01%. Michael Burry would check for concerns.